CA-WILSHIRE/LYXOR
Wilshire, a leading global financial services firm, has entered into a definitive agreement to acquire Lyxor Asset Management Inc. (“Lyxor U.S.”), a U.S.-based investment advisor with $20.8 billion in assets under management1, from Amundi, the largest European asset manager. Through this transaction, Wilshire will become a leading provider of hedge fund managed accounts and enhance its alternative investment offering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231030153915/en/
Lyxor U.S., a wholly owned subsidiary of Amundi Holdings US, Inc., is a provider of risk-managed, alternative and hedge fund investment solutions to institutional investors in North America. Lyxor U.S. was previously the U.S. subsidiary of Lyxor, the major European ETF and liquid alternatives provider acquired by Amundi in 2021. Wilshire’s acquisition of Lyxor U.S. will enhance Wilshire’s alternatives capabilities, including implementation capabilities through hedge fund managed accounts, and incorporate Lyxor U.S.’s premier institutional client base to the Wilshire ecosystem.
Jason Schwarz, Wilshire Deputy CEO and President, said: “The alternatives space is a key area of strategic focus for Wilshire and an important part of many investment portfolios. This acquisition furthers our goal of delivering innovative alternative investment solutions to our client base and will provide Lyxor U.S. clients with access to Wilshire’s asset allocation and investment research insights, portfolio construction capabilities, and more. Together with Lyxor U.S.’s leading alternatives platform and talented team, we will have an enhanced ability to deliver compelling investment opportunities for our clients.”
Andrew Dabinett, CEO of Lyxor U.S., said: “We have found an ideal partner in Wilshire, a firm tasked with solving many of the most complex investment challenges on behalf of a world-class client base. With Wilshire’s brand, experience, and core capabilities, we believe we will be well positioned to deliver enduring value to our clients and win new business.”
Scott Chan, Deputy Chief Investment Officer of the California State Teachers’ Retirement System (CalSTRS), said: “We’ve worked with Lyxor, a key partner of our Risk Mitigating Strategies team, for over ten years, and we look forward to continuing our long-term partnership. The acquisition by Wilshire will provide us access to a broader range of alternatives expertise and capabilities, which supports our overall mission of providing California’s public educators with a secure retirement. We thank Amundi for the thoughtful and constructive engagement its team has provided throughout this process.”
Amundi will continue to focus on growing its asset management and distribution capabilities in the Americas, including Amundi US, where it has operated since 1928. Amundi reaffirms its commitment to expanding its liquid alternatives business globally outside the U.S.
The transaction, which has no material financial impact on Amundi, is subject to customary closing conditions and is expected to close in the fourth quarter. Financial terms were not disclosed.
Wilshire was advised by Solomon Partners and Kirkland & Ellis LLP, and Amundi was advised by PJT Partners and Clifford Chance LLP.
About Wilshire
Wilshire is a leading global financial services firm and trusted partner to a diverse range of more than 500 leading institutional investors and financial intermediaries. Our clients rely on us to improve investment outcomes for a better future. Wilshire advises on over $1.3 trillion in assets and manages $88 billion in assets as of June 30, 2023. Wilshire is headquartered in the United States with offices worldwide.
About Amundi
Amundi, the leading European asset manager, ranking among the top 10 global players2, offers its 100 million clients - retail, institutional and corporate - a complete range of savings and investment solutions in active and passive management, in traditional or real assets. This offering is enhanced with IT tools and services to cover the entire savings value chain. A subsidiary of the Crédit Agricole group and listed on the stock exchange, Amundi currently manages more than €1.95 trillion of assets3.
With its six international investment hubs4, financial and extra-financial research capabilities and long-standing commitment to responsible investment, Amundi is a key player in the asset management landscape.
Amundi clients benefit from the expertise and advice of 5,400 employees in 35 countries.
Amundi, a trusted partner, working every day in the interest of its clients and society
www.amundi.com LinkedIn Twitter Facebook
______________________
1 As of June 30, 2023
2 Source: IPE “Top 500 Asset Managers” published in June 2023, based on assets under management as at 31/12/2022
3 Amundi data as at 30/09/2023
4 Boston, Dublin, London, Milan, Paris and Tokyo
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231030153915/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom